The miRNA profiling in PANC-1, PANC-1 GEM 100 and PANC-1 GEM1500 cells. Homo sapiens

Gemcitabine has been a first-line therapeutic agent for pancreatic ductal adenocarcinoma (PDAC) pancreatic cancer; however, acquisition of resistance to gemcitabine remains a major challenge. We analyzed miRNAs expression profiles by array-based miRNAs analysis between gemcitabine–resistant (PANC-1/GEM) and parental PANC-1 cells. Overall design: The three PDAC cells including PANC-1, PANC-1 GEM 100 and PANC-1 GEM1500 were harvested and RNA were isolated. Two independent experiments were performed for each group.

吉西他滨（Gemcitabine）是胰腺导管腺癌（pancreatic ductal adenocarcinoma, PDAC，即胰腺癌）的一线治疗药物，但吉西他滨耐药的发生仍是当前亟待解决的主要临床挑战。本研究采用基于微阵列芯片的miRNA分析技术，对比了吉西他滨耐药细胞（PANC-1/GEM）与其亲本PANC-1细胞的miRNA表达谱。
整体实验设计：本研究收集了PANC-1、PANC-1 GEM 100及PANC-1 GEM1500三株胰腺导管腺癌细胞，提取总RNA；每组均独立重复两次实验。